<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Essential features of common EC methods available in the United States</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Essential features of common EC methods available in the United States</h1>
<div class="graphic"><div class="figure"><div class="ttl">Essential features of common EC methods available in the United States</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Feature</td> <td class="subtitle1">Copper IUD</td> <td class="subtitle1">Levonorgestrel 52 mg IUD</td> <td class="subtitle1">Ulipristal acetate 30 mg</td> <td class="subtitle1">Levonorgestrel 1.5 mg</td> </tr> <tr class="divider_bottom"> <td>Pregnancy risk</td> <td><span style="white-space: nowrap;">0.1%<sup>[1]</sup></span></td> <td><span style="white-space: nowrap;">0.3%<sup>[4]</sup></span></td> <td>1.2 to <span style="white-space: nowrap;">1.8%<sup>[2,3]</sup></span></td> <td>1.7 to <span style="white-space: nowrap;">2.6%<sup>[2,3]</sup></span></td> </tr> <tr class="divider_bottom"> <td>Timing of use relative to UPI</td> <td>Typically, up to 5 days after UPI, but may be effective at any time in the menstrual cycle when urine pregnancy test is <span style="white-space: nowrap;">negative<sup>[1,5,6]</sup></span></td> <td>Current best evidence, up to 5 days after UPI, but may be effective at any time in the menstrual cycle when urine pregnancy test is <span style="white-space: nowrap;">negative<sup>[8]</sup></span></td> <td>Up to 5 days after <span style="white-space: nowrap;">UPI<sup>[7]</sup></span></td> <td>Up to 3 days after UPI, although may have efficacy up to 5 <span style="white-space: nowrap;">days<sup>[7]</sup></span></td> </tr> <tr class="divider_bottom"> <td>Timing of use relative to predicted ovulation</td> <td>Highly effective at any time in the cycle</td> <td>Highly effective at any time in the cycle</td> <td>Effective until the LH <span style="white-space: nowrap;">peak<sup>[9]</sup></span></td> <td>Effective until the LH surge <span style="white-space: nowrap;">begins<sup>[9]</sup></span></td> </tr> <tr class="divider_bottom"> <td>Availability and access</td> <td>Requires office visit and clinician insertion</td> <td>Requires office visit and clinician insertion</td> <td>Requires prescription</td> <td>Available OTC</td> </tr> <tr class="divider_bottom"> <td>Cost</td> <td>Covered by insurance, though high deductible can limit access; highest cost for uninsured</td> <td>Covered by insurance, though high deductible can limit access; highest cost for uninsured</td> <td>Covered by insurance: <ul class="decimal_heading"> <li>$50 self-pay at pharmacy</li> <li>$67 available online</li> </ul> </td> <td> <p>$40 to $50 OTC in pharmacies</p> $10 to $25 online, though shipping necessitates advanced provision for some websites</td> </tr> <tr class="divider_bottom"> <td>Relationship to starting progestin-containing contraception</td> <td>N/A, effective for contraception immediately</td> <td>N/A, effective for contraception immediately</td> <td>Wait 5 days to <span style="white-space: nowrap;">begin<sup>[10]</sup></span></td> <td>May start <span style="white-space: nowrap;">immediately<sup>[10]</sup></span></td> </tr> <tr class="divider_bottom"> <td>BMI pregnancy risk</td> <td>Highly effective regardless of BMI</td> <td>Highly effective regardless of BMI</td> <td> <p>BMI 25 to 29.9 = 1.1%</p> BMI ≥30 = <span style="white-space: nowrap;">2.6%<sup>[11]</sup></span></td> <td> <p>BMI 25 to 29.9 = 2.5%</p> BMI ≥30 = <span style="white-space: nowrap;">5.8%<sup>[11]</sup></span></td> </tr> <tr> <td>Works to prevent pregnancy if additional UPI in same cycle</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>No</td> </tr> </tbody></table></div><div class="graphic_footnotes">EC: emergency contraception; 

	IUD: intrauterine device; 

	UPI: unprotected intercourse; 

	LH: luteinizing hormone; 

	OTC: over the counter; 

	N/A: not applicable; 

	BMI: body mass index.</div><div class="graphic_reference">References:

	<ol>
<li>Cleland K, Zhu H, Goldstuck N, et al. The efficacy of intrauterine devices for emergency contraception: A systematic review of 35 years of experience. Hum Reprod 2012; 27:1994.</li>
<li>Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010; 375:555.</li>
<li>Shen J, Che Y, Showell E, et al. Interventions for emergency contraception. Cochrane Database Syst Rev 2019; :CD001324.</li>
<li>Turok DK, Gero A, Simmons RG, et al. Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception. N Engl J Med 2021; 384:335.</li>
<li>Turok DK, Godfrey EM, Wojdyla D, et al. Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle. Hum Reprod 2013; 28:2672.</li>
<li>Thompson I, Sanders JN, Schwarz EB, et al. Copper intrauterine device placement 6-14 days after unprotected sex. Contraception 2019; 100:219.</li>
<li>Emergency Contraceptive Pills: Medical and Service Delivery Guidance. International Consortium for Emergency Contraception 2018. https://www.cecinfo.org/wp-content/uploads/2018/12/ICEC-guides_FINAL.pdf (Accessed on March 09, 2019).</li>
<li>Boraas C, Sanders JN, Schwarz EB, et al. Risk of pregnancy with levonorgestrel-releasing intrauterine system placement 6-14 days after unprotected sexual intercourse. Obstet Gynecol 2021.</li>
<li>Noé G, Croxatto HB, Salvatierra AM, et al. Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception 2011; 84:486.</li>
<li>Providing Ongoing Hormonal Contraception after Use of Emergency Contraceptive Pills. American Society for Emergency Contraception 2016. http://americansocietyforec.org/uploads/3/4/5/6/34568220/asec_fact_sheet-_hormonal_contraception_after_ec.pdf (Accessed on March 09, 2019).</li>
<li>Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011; 84:363.</li>
</ol></div><div id="graphicVersion">Graphic 120627 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
